Anti-IL13(cendakimab biosimilar) mAb Cat. No. BME100451



PRODUCT INFORMATION

| Uniprot ID | P35225 |
|---------------------------------|---|
| Common Name | ABT-308;ABT308;CC 93538;CC93538;CC-93538;RPC 4046;RPC4046;RPC-4046 |
| Conjugate | Unconjugated |
| Synonyms | P600;IL-13;NC30 |
| Applications | N/A |
| Recommended Dilutions | N/A |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Host Species | N/A |
| lgG type | lgG1 |
| Reactivity | Human |
| Target | IL13 |
| Description | Anti-IL13(cendakimab biosimilar]]IgG1) mAb |
| Delivery | 3-4 weeks |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. Research grade biosimilar. Not for use in |
| Background | therapeutic or diagnostic procedures for humans or animals. |
| Usage | Research use only |
| | |

